SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-002940
Filing Date
2023-01-30
Accepted
2023-01-30 16:30:43
Documents
14
Period of Report
2023-01-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 49138
2 ex10-1.htm EX-10.1 96850
3 ex10-2.htm EX-10.2 118293
  Complete submission text file 0001493152-23-002940.txt   483561

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prph-20230126.xsd EX-101.SCH 3239
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prph-20230126_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prph-20230126_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3607
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 23568228
SIC: 2834 Pharmaceutical Preparations